Clinical Trial Update: Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A phase 2 neoadjuvant trial of WX-0593 for resectable ALK-positive or ROS1-positive non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Ros1-positive Non-small Cell Lung Cancer

Drugs mentioned

• WX-0593

Snippet

Sponsor: Pingping Song | Conditions: Non-Small Cell Lung Cancer(NSCLC) | Phase 2 | Status: RECRUITING